KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Net Income towards Common Stockholders (2020 - 2025)

Historic Net Income towards Common Stockholders for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$162.3 million.

  • Recursion Pharmaceuticals' Net Income towards Common Stockholders fell 6929.22% to -$162.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.5 million, marking a year-over-year decrease of 8942.19%. This contributed to the annual value of -$463.7 million for FY2024, which is 4133.16% down from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Net Income towards Common Stockholders of -$162.3 million as of Q3 2025, which was down 6929.22% from -$171.9 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Net Income towards Common Stockholders registered a high of -$30.5 million during Q1 2021, and its lowest value of -$202.5 million during Q1 2025.
  • Its 5-year average for Net Income towards Common Stockholders is -$92.5 million, with a median of -$76.7 million in 2023.
  • In the last 5 years, Recursion Pharmaceuticals' Net Income towards Common Stockholders crashed by 15393.85% in 2021 and then soared by 612.38% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$65.0 million in 2021, then rose by 6.12% to -$61.0 million in 2022, then tumbled by 52.5% to -$93.0 million in 2023, then tumbled by 92.38% to -$178.9 million in 2024, then grew by 9.31% to -$162.3 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$162.3 million for Q3 2025, versus -$171.9 million for Q2 2025 and -$202.5 million for Q1 2025.